Comparison of macitentan and bosentan on right ventricular remodeling in a rat model of non-vasoreactive pulmonary hypertension

Journal of Cardiovascular Pharmacology

Volumn 66, Issue 5, 2015, Pages 457-467

  Iglarz, Marc ^a   Landskroner, Kyle ^a   Bauer, Yasmina ^a   Vercauteren, Magali ^a   Rey, Markus ^a   Renault, Berengère ^a   Studer, Rolf ^a   Vezzali, Enrico ^a   Freti, Diego ^a   Hadana, Hakim ^a   Schläpfer, Manuela ^a   Cattaneo, Christophe ^a   Bortolamiol, Céline ^a   Weber, Edgar ^a   Whitby, Brian R ^b   Delahaye, Stéphane ^a   Wanner, Daniel ^a   Steiner, Pauline ^a   Nayler, Oliver ^a   Hess, Patrick ^a   Clozel, Martine ^a   more..

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b Department of Genetic and Molecular Toxicology   (United Kingdom)

Author keywords

Bosentan; Endothelin; Macitentan; Pulmonary hypertension; Right ventricle

Indexed keywords

BLEOMYCIN; BOSENTAN; COLLAGEN TYPE 1; FOLLISTATIN; GALECTIN 3; INHIBIN A; MACITENTAN; PROTEIN LYSINE 6 OXIDASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ENDOTHELIN RECEPTOR ANTAGONIST; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DISEASE MODEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; GENE EXPRESSION REGULATION; HEART; HEART MUSCLE CELL; HEART PROTECTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE REMODELING; HEART VENTRICLE REMODELING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LUNG; LUNG PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; SINGLE DRUG DOSE; SMOOTH MUSCLE FIBER; TISSUE DISTRIBUTION; VASCULAR REMODELING; ANIMAL; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; METABOLISM; PATHOPHYSIOLOGY; PULMONARY ARTERY; TIME FACTOR; WISTAR RAT;

ANIMALS; BLEOMYCIN; DISEASE MODELS, ANIMAL; ENDOTHELIN RECEPTOR ANTAGONISTS; GENE EXPRESSION REGULATION; HEART VENTRICLES; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; PULMONARY ARTERY; PYRIMIDINES; RATS, WISTAR; SULFONAMIDES; TIME FACTORS; VASCULAR REMODELING; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR REMODELING;

EID: 84946922536     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000296     Document Type: Article

References (38)

1. Iglarz M, Clozel M. At the heart of tissue: endothelin system and endorgan damage. Clin Sci (Lond). 2010;119:453-463.
2. Dagassan PH, Breu V, Clozel M, et al. Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol. 1996;27:147-153.
3. Bauer M, Wilkens H, Langer F, et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation. 2002;105:1034-1036.
4. Desmarets J, Gresser O, Guedin D, et al. Interaction of endothelin-1 with cloned bovine ETA receptors: biochemical parameters and functional consequences. Biochemistry. 1996;35:14868-14875.
5. Frelin C, Guedin D. Why are circulating concentrations of endothelin-1 so low? Cardiovasc Res. 1994;28:1613-1622.
6. Sutsch G, Bertel O, Rickenbacher P, et al. Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. Am J Cardiol. 2000;85:973-976.
7. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
8. Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093-2100.
9. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809-818.
10. Gatfield J, Mueller Grandjean C, Sasse T, et al. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One. 2012;7:e47662.
11. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327:736-745.
12. Bolli MH, Boss C, Binkert C, et al. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl) oxy]ethoxy]-4-pyrimidinyl]-N'-p ropylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem. 2012;55:7849-7861.
13. Iglarz M, Bossu A, Wanner D, et al. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension. Life Sci. 2014;118:333-339.
14. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105-3111.
15. Rey M, Weber EW, Hess PD. Simultaneous pulmonary and systemic blood pressure and ECG interval measurement in conscious, freely moving rats. J Am Assoc Lab Anim Sci. 2012;51:231-238.
16. Mouchaers KT, Schalij I, De Boer MA, et al. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J. 2010;36:800-807.
17. Henkens IR, Mouchaers KT, Vliegen HW, et al. Early changes in rat hearts with developing pulmonary arterial hypertension can be detected with three-dimensional electrocardiography. Am J Physiol Heart Circ Physiol. 2007;293:H1300-H1307.
18. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-2537.
19. Iglarz M, Steiner P, Wanner D, et al. Vascular effects of endothelin receptor antagonists depends on their selectivity for ETA vs. ETB receptors and on the functionality of endothelial ETB receptors. J Cardiovasc Pharmacol. 2015. In press.
20. Williams JH Jr, Bodell P, Hosseini S, et al. Haemodynamic sequelae of pulmonary fibrosis following intratracheal bleomycin in rats. Cardiovasc Res. 1992;26:401-408.
21. Sato S, Kato S, Arisaka Y, et al. Changes in pulmonary hemodynamics during normoxia and hypoxia in awake rats treated with intratracheal bleomycin. Tohoku J Exp Med. 1993;169:233-244.
22. Mutsaers SE, Foster ML, Chambers RC, et al. Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. Am J Respir Cell Mol Biol. 1998;18:611-619.
23. Park SH, Saleh D, Giaid A, et al. Increased endothelin-1 in bleomycininduced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med. 1997;156:600-608.
24. Saleh D, Furukawa K, Tsao MS, et al. Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol. 1997;16:187-193.
25. Adamson IY, Bowden DH. The pathogenesis of bloemycin-induced pulmonary fibrosis in mice. Am J Pathol. 1974;77:185-197.
26. Ryan J, Bloch K, Archer SL. Rodent models of pulmonary hypertension: harmonisation with the world health organisation's categorisation of human PH. Int J Clin Pract Suppl. 2011:15-34.
27. Hess P, Clozel M, Clozel JP. Telemetry monitoring of pulmonary arterial pressure in freely moving rats. J Appl Physiol (1985). 1996;81:1027-1032.
28. Choudhary G, Troncales F, Martin D, et al. Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension. J Heart Lung Transplant. 2011;30:827-833.
29. Rafikova O, Rafikov R, Kumar S, et al. Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension. Free Radic Biol Med. 2013;56:28-43.
30. Gatfield J, Mueller Grandjean C, Bur D, et al. Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis. PLoS One. 2014;9:e107809.
31. Kummer O, Haschke M, Hammann F, et al. Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. Eur J Pharm Sci. 2009;38:384-388.
32. Mauritz GJ, Kind T, Marcus JT, et al. Progressive changes in right ventricular geometric shortening and long-term survival in pulmonary arterial hypertension. Chest. 2012;141:935-943.
33. To WS, Midwood KS. Plasma and cellular fibronectin: distinct and independent functions during tissue repair. Fibrogenesis Tissue Repair. 2011;4:21.
34. Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012;60:1249-1256.
35. Bjornstad JL, Neverdal NO, Vengen OA, et al. Alterations in circulating activin a, GDF-15, TGF-Beta3 and MMP-2, -3, and -9 during one year of left ventricular reverse remodelling in patients operated for severe aortic stenosis. Eur J Heart Fail. 2008;10:1201-1207.
36. Yndestad A, Ueland T, Oie E, et al. Elevated levels of activin a in heart failure: potential role in myocardial remodeling. Circulation. 2004;109:1379-1385.
37. Hashimoto O, Nakamura T, Shoji H, et al. A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate. J Biol Chem. 1997;272:13835-13842.
38. Yndestad A, Larsen KO, Oie E, et al. Elevated levels of activin a in clinical and experimental pulmonary hypertension. J Appl Physiol (1985). 2009;106:1356-1364.